

HALOZYME THERAPEUTICS INC  
Form 4  
June 02, 2016

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KIRK RANDAL J

2. Issuer Name and Ticker or Trading Symbol  
HALOZYME THERAPEUTICS INC [HALO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O THIRD SECURITY, LLC, 1881 GROVE AVENUE

05/31/2016

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RADFORD, VA 24141

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	05/31/2016		J(1)		1,326,320 (1)	D	by NRM IV (2)
Common Stock	05/31/2016		J(1)		81,795 (1)	A	by Staff 2001 (2)
Common Stock	05/31/2016		J(1)		371,186 (1)	A	by R.J. Kirk DOT (2)
Common Stock	05/31/2016		J(1)		372 (1)	A	by Lotus (2)
	05/31/2016		J(1)		9,954 (1)	A	

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock									by JPK 2008 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	9,954 <sup>(1)</sup>	A	Ⓛ	302,954	I		by MGK 2008 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	9,954 <sup>(1)</sup>	A	Ⓛ	302,954	I		by ZSK 2008 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	23,259 <sup>(1)</sup>	A	Ⓛ	354,654	I		by JPK 2009 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	23,259 <sup>(1)</sup>	A	Ⓛ	354,653	I		by MGK 2009 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	2,235 <sup>(1)</sup>	A	Ⓛ	2,235	I		by ZSK 2009 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	27,260 <sup>(1)</sup>	A	Ⓛ	290,460	I		by JPK 2012 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	4,382 <sup>(1)</sup>	A	Ⓛ	46,701	I		by Kellie L. Banks LTT <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	131,144 <sup>(1)</sup>	A	Ⓛ	131,144	I		by Senior Staff 2006 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	65,572 <sup>(1)</sup>	A	Ⓛ	65,572	I		by Staff 2006 <sup>(2)</sup>
Common Stock	05/31/2016	J <sup>(1)</sup>	21,858 <sup>(1)</sup>	A	Ⓛ	21,858	I		by Incentive 2006 <sup>(2)</sup>
Common Stock						3,977,445	I		by Kapital Joe <sup>(2)</sup>
Common Stock						6,328,853	I		by NRM V <sup>(2)</sup>
Common Stock						3,538,253	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying	8. Price of Derivative Security	9. Nu Deriv Secur
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	--------------	--	-----------------------------------	---------------------------------	-------------------

